Zura Bio director granted 51,000 stock options

Zura Bio Ltd director Steven J. Schoch received a grant of stock options as compensation.

Rhea-AI Filing Summary

Zura Bio Ltd director Steven J. Schoch received a grant of stock options as compensation. The award covers 51,000 options to buy Class A Ordinary Shares at an exercise price of $3.62 per share, expiring on June 17, 2036. The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, with any remaining unvested portion vesting immediately before the next annual meeting of shareholders, subject to his continued service.

Insider Trade Summary

Grant/Award: 51,000 shares

Grant/Award 1 txn

Insider Schoch Steven J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	51,000	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 51,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Key Figures

Stock options granted: 51,000 options Exercise price: $3.62 per share Underlying shares: 51,000 Class A Ordinary Shares +2 more

5 metrics

Stock options granted 51,000 options Grant on June 17, 2026

Exercise price $3.62 per share Strike price of granted options

Underlying shares 51,000 Class A Ordinary Shares Shares subject to the option

Expiration date June 17, 2036 Option term end

Total options after grant 51,000 options Derivative holdings following transaction

Key Terms

Share Option (Right to Buy), Class A Ordinary Shares, vests in twelve substantially equal monthly installments, exercise price, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

vests in twelve substantially equal monthly installments financial

"This option vests in twelve substantially equal monthly installments over a one-year period"

exercise price financial

"conversion_or_exercise_price: "3.6200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) director Steven J. Schoch report in this Form 4?

Steven J. Schoch reported receiving a grant of 51,000 stock options. These options give him the right to buy Zura Bio Class A Ordinary Shares at a fixed exercise price as part of his director compensation package, subject to a defined vesting schedule.

How many Zura Bio (ZURA) stock options were granted to Steven J. Schoch?

He was granted 51,000 stock options linked to Class A Ordinary Shares. This entire amount represents his total derivative position following the transaction, indicating a new equity-based incentive aligned with Zura Bio’s long-term performance and his role on the board.

What is the exercise price and expiration date of Steven J. Schoch’s Zura Bio options?

The options carry an exercise price of $3.62 per share and expire on June 17, 2036. This long-dated expiration gives Schoch a multi-year window to potentially exercise the options if performance and share price conditions make it attractive.

How do Steven J. Schoch’s Zura Bio options vest over time?

The option vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion then vests immediately before the next annual shareholder meeting, provided Schoch continues to serve as a director through the applicable vesting dates.

Does this Zura Bio Form 4 show any open-market buying or selling by Steven J. Schoch?

No open-market purchases or sales are reported. The filing shows only a grant of 51,000 stock options classified as a grant or award acquisition, a typical equity compensation arrangement for a director rather than a discretionary market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoch Steven J

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.62	06/17/2026		A		51,000		(1)	06/17/2036	Class A Ordinary Shares	51,000	$0	51,000	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)